Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-30T23:03:02.505Z Has data issue: false hasContentIssue false
  • English
  • Français

Unusual lymphoproliferative oropharyngeal lesions in heart and heart-lung transplant recipients

Published online by Cambridge University Press:  29 June 2007

James W. Fairley ,
Beverley J. Hunt ,
Garry W. Glover ,
Rosemary C. Radley-Smith  and
Magdi H. Yacoub
James W. Fairley*
Affiliation:
Department of ENT Surgery, Mount Vcrnon Hospital, Northwood, Middlesex HA6 2RN
Beverley J. Hunt
Affiliation:
Department of Senior Registrar in Research Haematology, Harefield Hospital, Harefield, Middlesex UB9 6JH
Garry W. Glover
Affiliation:
Department of ENT Surgery, Mount Vcrnon Hospital, Northwood, Middlesex HA6 2RN
Rosemary C. Radley-Smith
Affiliation:
Department of Consultant Paediatric Cardiologist, Harefield Hospital, Harefield, Middlesex UB9 6JH
Magdi H. Yacoub
Affiliation:
Department of Cardiothoracic Surgery, Harefield Hospital, Harefield, Middlesex UB9 6JH
*
Mr. J. W. Fairley, Senior ENT Registrar, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF.
Get access Rights & Permissions [Opens in a new window]

Abstract

Three unusual cases of oropharyngeal lympho-proliferative lesions were seen in recipients of heart and heart-lung transplants. Two caused acute upper respiratory obstruction necessitating urgent ENT intervention. All patients were receiving immunosuppressive drugs including cyclosporin. The two obstructive cases were adenotonsillar enlargement in a 6-year-old, and a tumour of the tonsil and tongue base with cervical lymph node enlargement in a 32-year-old male. Both were caused by Epstein-Barr Virus-associated lymphoproliferative disorder. The third patient, a 32-year-old female, had a presumed low grade T-cell lymphoma that regressed spontaneously.

Histopathological diagnosis of these lympho-proliferative disorders after transplantation usually requires immunocytochemistry to distinguish polyclonal proliferative disorders from true lymphoma. Polyclonal lymphoproliferative disorders after transplantation do not usually require aggressive cytoreductive therapy, but respond to simple measures such as the reduction of immunosuppression.

Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 104 , Issue 9 , September 1990 , pp. 720 - 724
Copyright
Copyright © JLO (1984) Limited 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allday, M. J., Crawford, D. H. (1988) Role of epithelium in EBV persistence and pathogenesis of B-cell tumours. Lancet, i: 855–857.CrossRefGoogle Scholar
Anon (editorial) (1988) Epstein-Barr virus and T-cell lymphoma. Lancet, ii: 723–724.Google Scholar
Banner, N. R., Fitzgerald, M., Khaghani, A., Aravot, D., Reid, C., Mitchell, A. G., Radley-Smith, R., Yacoub, M. H. (1987) Cardiac transplantation at Harefield Hospital. In Clinical Transplants Terasaki, P. (ed.) pp 17–26.Los Angeles.Google Scholar
Colby, B. M., Shaw, J. E., Elion, G. B., Pagano, J. S. (1980) Acyclovir inhibition of Epstein-Barr virus replication. Proceedings of the National Academy of Sciences of the USA, 77: 5163–5166.Google Scholar
Hanto, D. W., Frizzeria, D., Purtilo, D. T., et al. (1981) Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Research, 41: 4253–4261.Google ScholarPubMed
Harrington, D. S., Weisenburger, D. D., Purtilo, D. T. (1988) Epstein-Barr virus associated lymphoproliferative lesions. Clinics in Laboratory Medicine, 8(1): 97–118.CrossRefGoogle ScholarPubMed
Macleod, A. M., Catto, G. R. D. (1988) Cancer after transplantation, the risks are small. British Medical Journal, 297: 4–5.CrossRefGoogle Scholar
Rickinson, A. B., Moss, D. J., Wallace, L. E., Rowe, M., Misko, I. S., Epstein, M. A., Pope, J. H. (1981) Long term T-cell mediated immunity to Epstein-Barr virus. Cancer Research, 41: 4216–4221.Google ScholarPubMed